Oppenheimer & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$279K Hold
4,656
– – ﹤0.01% 1465
2026
Q2
$266K Buy
+4,656
New +$255K ﹤0.01% 1526
2026
Q1
– Sell
-7,847
Closed -$466K – 1697
2025
Q4
$466K Sell
7,847
-2,028
-21% -$110K 0.01% 1101
2025
Q3
$535K Buy
9,875
+728
+8% +$41.6K 0.01% 1150
2025
Q2
$503K Buy
9,147
+3,736
+69% +$220K 0.01% 1149
2025
Q1
$383K Buy
+5,411
New +$364K 0.01% 1175
2024
Q2
– Sell
-4,714
Closed -$412K – 1441
2024
Q1
$412K Buy
4,714
+1,949
+70% +$174K 0.01% 1063
2023
Q4
$267K Buy
2,765
+71
+3% +$6.28K ﹤0.01% 1188
2023
Q3
$238K Sell
2,694
-602
-18% -$53.6K ﹤0.01% 1211
2023
Q2
$286K Buy
3,296
+369
+13% +$34.7K 0.01% 1174
2023
Q1
$285K Buy
+2,927
New +$303K 0.01% 1140
2015
Q3
– Sell
-11,831
Closed -$1.62M – 1361
2015
Q2
$1.62M Buy
+11,831
New +$1.47M 0.05% 475
2014
Q2
– Sell
-3,214
Closed -$219K – 1415
2014
Q1
$219K Sell
3,214
-2
-0.1% -$147 0.01% 1193
2013
Q4
$226K Buy
+3,216
New +$218K 0.01% 1152

Other funds holding BMRN

Oppenheimer & Co's BMRN Position: Q3 2026 in Review

Oppenheimer & Co held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 4,656 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Oppenheimer & Co first reported a position in BMRN in Q4 2013 and has held it in 14 quarters since. The position peaked at $1.62M in Q2 2015. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Oppenheimer & Co held 4,656 shares of BioMarin Pharmaceuticals worth $279K as of Q3 2026.
  • Oppenheimer & Co left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1465 holding.
  • Oppenheimer & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
  • Oppenheimer & Co's BioMarin Pharmaceuticals position peaked at $1.62M in Q2 2015.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.